JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Grigg, J. J.
Right arrow Articles by Anderson, E. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grigg, J. J.
Right arrow Articles by Anderson, E. G.

Competitive and noncompetitive N-methyl-D-aspartate antagonists modify hypoxia-induced membrane potential changes and protect rat hippocampal slices from functional failure: a quantitative comparison

JJ Grigg and EG Anderson

Department of Pharmacology, University of Illinois College of Medicine, Chicago.

Hippocampal slice survival after hypoxia was improved by exposure to competitive and noncompetitive N-methyl-D-aspartate (NMDA) antagonists. The rapid blockade and reappearance of synaptic transmission during hypoxia was not altered by these antagonists. However, [(+)-5-methyl- 10, 11-dihydro-5H-dibenzo[a,d] cyclohepten-5, 10-imine maleate (MK-801) (50 microM) and 2-amino-5-phosphonopentanoic acid (dl-AP5) (25 microM) delayed the disappearance of these reactivated orthodromic population spikes. Intracellular recordings showed that MK-801 and dl-AP5 delayed the late, but not early, hypoxic depolarization of pyramidal cells, and improved recovery of membrane potential and input resistance (Rin) in many cells after reoxygenation. No untreated cells showed recovery. Thus, both competitive and noncompetitive NMDA antagonists decreased the hypoxia-induced depolarization and Rin. With the return of evoked population spikes as an index for recovery from hypoxia, the ED50 values for dl-AP5, MK-801, phencyclidine and dextromethorphan were 7.7, 4.5, 7.1 and 75 microM, respectively. Thus, in contrast to their higher affinities for the NMDA receptor MK-801 and phencyclidine were not significantly more potent than dl-AP5 in protecting hippocampal slices from hypoxia, and isobolographic analysis revealed dose-additive interactions. The unexpectedly low potency of the noncompetitive NMDA antagonists in protecting against hypoxia is attributed to magnesium in the buffer and the hypoxia-induced membrane depolarization, both of which have been shown to reduce the effectiveness of noncompetitive NMDA antagonists.

Volume 253, Issue 1, pp. 130-135, 04/01/1990
Copyright © 1990 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
Physiol. Rev.Home page
G. G. Somjen
Mechanisms of Spreading Depression and Hypoxic Spreading Depression-Like Depolarization
Physiol Rev, July 1, 2001; 81(3): 1065 - 1096.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
P. Lipton
Ischemic Cell Death in Brain Neurons
Physiol Rev, October 1, 1999; 79(4): 1431 - 1568.
[Abstract] [Full Text] [PDF]


Home page
J. Neurophysiol.Home page
E. Tanaka, S. Yamamoto, Y. Kudo, S. Mihara, and H. Higashi
Mechanisms Underlying the Rapid Depolarization Produced by Deprivation of Oxygen and Glucose in Rat Hippocampal CA1 Neurons In Vitro
J Neurophysiol, August 1, 1997; 78(2): 891 - 902.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
R. F. Villa and A. Gorini
Pharmacology of Lazaroids and Brain Energy Metabolism: A Review
Pharmacol. Rev., March 1, 1997; 49(1): 99 - 136.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1990 by the American Society for Pharmacology and Experimental Therapeutics.